Novo Holdings would like to congratulate our portfolio company Bolt Biotherapeutics Inc (NASDAQ: BOLT) on their recent IPO.  Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

For further information, please find the full statement here.